Product Description
Mechanisms of Action: PR Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Ukraine
Approved Indications: None
Known Adverse Events: None
Company: AS Kevelt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Endometrial Cancer|Papillary Carcinoma|Papillary Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX-EC-2-02 | P2 |
Terminated |
Endometrial Cancer |
2020-07-17 |
|
| VX-EC-2-2013 | P2 |
Unknown status |
Endometrial Cancer |
2018-01-01 |
|
| 2014-001434-29 | P2 |
Active, not recruiting |
Papillary Adenocarcinoma|Papillary Carcinoma|Endometrial Cancer |
2017-09-22 |